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http://dx.doi.org/10.1016/j.cgh.2016.01.017The frequent publication of clinical study dataimpacts the practice of evidence-based medicine
in inﬂammatory bowel disease (IBD) management. Inter-
preting and incorporating these data into daily clinical
practice are challenging. To assess the relative strength
and limitations of our current knowledge in IBD, a sys-
tematic clinical appraisal of the medical literature was
conducted by a panel of IBD leaders that was chaired
by Prof Geert D’Haens of the Inﬂammatory Bowel Dis-
ease Centre of the Academic Medical Centre in Amster-
dam. Results of this literature appraisal were then
compared with the results of an international clinical
practice survey of gastroenterologists to reveal any dis-
crepancies between published evidence and current clin-
ical practice. The treatment areas addressed in both the
literature appraisal and the gastroenterologist survey
included anti–tumor necrosis factor-a therapy, deﬁni-
tions of treatment failure, use of drug levels, and long-
term risks of therapy. Gastroenterologists were asked
via an e-mailed survey to vote on 6 clinical scenario
statements by using a Likert scale of acceptance or rejec-
tion. Concurrently, the panel of IBD leaders critically
appraised the existing medical literature to assess the
relative strength and limitations related to each state-
ment and voted on the same statements by using the
same Likert scale. Voting results from the survey and
the panel were compared and analyzed. The panel’s anal-
ysis and discussion of the literature produced additional
questions for consideration. All respondents to the
gastroenterologist survey were in practice, and approxi-
mately 74% reported spending 25% of their time
managing IBD patients. Discordant voting between the
panel and the surveyed gastroenterologists revealed
there are unmet educational needs to enhance the level
of knowledge surrounding difﬁcult questions in IBD
management. Voting results for all 6 statements are pre-
sented in this interactive publication http://education.
cghjournal.org/video/976/5/CD-UC-clinical-appraisal.
See how your practice patterns and views compare with
those of your peers and the panel of IBD leaders.Clinical Gastroenterology and Hepatology 2016;14:638–639Author Disclosures
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